Windtree Therapeutics, Inc. (WINT)
OTCMKTS · Delayed Price · Currency is USD
0.0199
+0.0001 (0.51%)
At close: Jan 23, 2026
Windtree Therapeutics Employees
Windtree Therapeutics had 14 employees as of December 31, 2024. The number of employees decreased by 6 or -30.00% compared to the previous year.
Employees
14
Change
-6
Growth
-30.00%
Revenue / Employee
n/a
Profits / Employee
-$3,487,929
Market Cap
741.19K
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 14 | -6 | -30.00% | 14 | 0 |
| Dec 31, 2022 | 20 | -13 | -39.39% | 20 | 0 |
| Dec 31, 2021 | 33 | 2 | 6.45% | 33 | 0 |
| Dec 31, 2020 | 31 | -1 | -3.13% | 31 | 0 |
| Dec 31, 2019 | 32 | -1 | -3.03% | 31 | 1 |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Emmaus Life Sciences | 35 |
| Hepion Pharmaceuticals | 22 |
| Altamira Therapeutics | 11 |
| Bio-Path Holdings | 10 |
| Lipella Pharmaceuticals | 7 |
| Sigyn Therapeutics | 4 |
| Regen BioPharma | 1 |
Windtree Therapeutics News
- 7 weeks ago - Windtree Therapeutics (WINT) to Acquire CommLoan: A Strategic Move - GuruFocus
- 2 months ago - Windtree Therapeutics (WINT) Eyes Potential Milestone Payments from License Agreement - GuruFocus
- 2 months ago - Windtree Therapeutics (WINT) Secures $7.5 Million in Strategic Agreement - GuruFocus
- 5 months ago - Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at ... - GuruFocus
- 5 months ago - BNB treasury firm plunges 77% after Nasdaq delisting notice - Cointelegraph
- 5 months ago - Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025 - GlobeNewsWire
- 6 months ago - Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption - GlobeNewsWire
- 6 months ago - BNB Rebounds to $780 After $520M Windtree Buy Commitment, Shows Signs of Stabilizing - CoinDesk